Tg2 Medicina33 Haploidentical transplantation and new cell therapies, interview with Fabio Ciceri

News & Events

Stay update

Tg2 Medicina33 Haploidentical transplantation and new cell therapies, interview with Fabio Ciceri ▾

Tg2 Medicina33 Haploidentical transplantation and new cell therapies, interview with Fabio Ciceri

http://www.tg2.rai.it/dl/RaiTV/programmi/media/ContentItem-54148dc1-81fa-4963-9721-38c09498de7f-tg2.html#p=0

We invite you to look at the first part of this tv report during which Dr. Ciceri explains the benefits of a new cell therapy in patients undergoing haploidentical haematopoietic stem cell transplantation, in the treatment of oncohaematological diseases (in italian)

Subscribe to press releases

Contacts

Investor Relations & Communication Manager
Phone: +39 02 21277.205
E-mail: investor.relations@molmed.com

Investors

Dear Users, we would like to inform you that, as of 30 September, AGC Biologics S.p.A. (formerly MolMed S.p.A.) is no longer listed on the Milan Stock Exchange and has become part of the AGC Biologics Group. For any information on the company and the group, you are kindly invited to consult the websitewww.agcbio.com.
The contents present on this portal (www.molmed.com) are updated until the date of September 30, 2020 and will be available for the time frame foreseen by applicable regulations.
In addition, the "work with us" section is still active, while the contact details are no longer accessible.

News & Events

Stay update

Tg2 Medicina33 Haploidentical transplantation and new cell therapies, interview with Fabio Ciceri ▾

Tg2 Medicina33 Haploidentical transplantation and new cell therapies, interview with Fabio Ciceri

Subscribe to press releases

About us

About us ▾

Pipeline

Pipeline ▾

GMP Solutions

GMP Solutions ▾

Investors

Investors ▾

Governance

Governance ▾

News & Events

News ▾